Lilly compound shows insulinotropic effect

US drug major Eli Lilly presented positive Phase II results for LY2189265, its investigational glucagon-like peptide-1 analog  administered subcutaneously once-weekly for the treatment of type 2  diabetes at the American Diabetes Association's annual scientific  sessions in New Orleans.

In the Phase II study, known as GBCJ, LY2189265 was significantly  superior to placebo in reducing key measures of glycemic control,  including fasting serum glucose and hemoglobin A1C. The agent also  showed an insulinotropic effect, suggesting it produced the desired  outcome in participants.

For all doses in this study, statistically-significant reductions in all  metabolic measures were observed. Both 1mg and 2mg doses of LY2189265  were significantly different from placebo, but no significant  differences between the doses were seen. LY2189265 was generally  well-tolerated. The incidence of hypoglycemic episodes was not  significantly different between the placebo and the treatment groups.  The most frequently-observed treatment-related adverse events were  nausea, diarrhea and abdominal distension. One patient was diagnosed  with clinical pancreatitis, following the 11th dose of LY2189265. The  subject remained in the study for observation and has fully recovered.